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Neurotransmitters (NTs) have recently received increasing appreciation as 
important immune modulators. The immune cells express receptors for many 
classes of NTs and the communication between NTs and their receptors establish 
neuro-immune interactions for regulating effective immune response in both 
central nervous system (CNS) and peripheral tissues. Metabotropic Glutamate 
Receptor 4 (mGluR4) is expressed at high level in CNS and plays a role in various 
physiological and pathophysiological processes in CNS. Recently, mGluR4 has been 
reported to be expressed on immune cells and have an impact on regulating the 
immune system. This chapter summarized the works associated with the immuno-
genic function of mGluR4 and its potential underlying mechanisms.
Keywords: metabotropic glutamate receptor (mGluR4), immune response, 
peripheral tissues, central nervous system (CNS), cancer, autoimmune diseases
1. Introduction
Neurotransmitters (NTs) have recently received increasing appreciation as 
important immune modulators. The immune cells express receptors for many 
classes of NTs and the communication between NTs and their receptors establish 
neuro-immune interactions for regulating effective immune response in both CNS 
and peripheral tissues [1]. Interestingly, the role of NTs is very complicated and 
the same NTs can even exert opposing effects for promoting or inhibiting tissue 
immunity in different contexts [2–6].
Studies of the NTs and their receptors in modulating immunity are limited 
and therein are important areas of investigations. L-Glutamate (Glu) is the major 
excitatory neurotransmitter in the mammalian CNS [7]. It acts via two classes of 
receptors, ligand gated ion channels (ionotropic receptors (iGluRs))-regulating 
rapid responses upon activation, and G-protein coupled (metabotropic) receptors-
modulating signal transduction cascades. Eight different types of mGluRs, mGluR1 
to mGluR8 are divided into groups I, II, and III on the basis of their intracellular 
signal transduction mechanisms, agonist pharmacology, and sequence homologies 
(see Figure 1) [8]. Group I includes mGluR1 and mGluR5, coupled to Gq protein; 
group II includes mGluR2 and mGluR3, coupled to Gi and Go proteins; group III 
includes mGluR4, mGluR6, mGluR7 and mGluR8, coupled to Gi and Go proteins in 
heterologous expression systems.
mGluR4 is expressed at high levels in CNS and plays a role in various physiologi-
cal and pathophysiological processes in CNS [9, 10], such as learning, memory, 
and cognitive impairment. In addition, growing evidence indicates that mGluRs 
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are expressed in the peripheral such as thymus and lymphocytes [11]. These results 
suggest a potential role of mGluR4 in immune regulation. In this chapter, we sum-
marized the association of mGluR4 with immune responses and its role in different 
diseases. The potential of mGluR4 as a novel therapeutic target in immune-related 
diseases was also discussed.
2. Expression of mGluR4 on immune cells
Clinical data indicated that elevated plasma concentrations of Glu are associ-
ated with immune deficiency [12, 13]. In addition, in vitro assays showed that high 
concentration of Glu (>100 uM) can inhibit mitogen-induced T-cell proliferation 
[12, 13]. Therefore, it is not surprising that immune cells express mGluRs. It has 
been proposed that mGluRs can mediate an emergency mechanism once high levels 
of Glu are reached.
Using immunostaining and Western blot analysis, Rezzani et al. observed the 
expression of mGluR4 in rat thymic cells [14]. The expression of mGluR4 was 
abundant in dendritic cells (DCs) and lymphocytes of the thymic medulla but was 
weak in lymphocytes of the cortex. It is interesting to note that a rapid inhibition 
on the expression of mGluR4 was induced in the rat thymus after treatment with 
cyclosporine (an immunosuppressant). The mGluR4 expression reached undetect-
able levels after a longer treatment regimen of cyclosporine.
Other evidence also pointed out that the expression of mGluRs is not exclusive 
to young immune cells because mature lymphocytes are activated by selective 
mGluRs ligands. In addition, rat peripheral lymphocytes responded by producing 
reactive oxygen species (ROS) when they were exposed to the group III mGluRs 
Figure 1. 
The summary of mGluRs families. mGluRs are classified into three families: group I, group II, and group III. 
In the CNS, activation of mGluRs from group I leads to the induction of phosphoinositide hydrolysis with 
formation of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The activation of groups II and III 
receptors induce a decrease on the intracellular levels of cyclic adenosine monophosphate (cAMP) [7].
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agonist L-2-amino-4-phosphonobutyric acid (L-AP4) [15]. ROS play important 
roles in T-cell biology and participate in activation-induced T cell apoptosis and 
hence in the termination of the immune response [16]. Moreover, DCs are capable 
of secreting glutamate when interacting with T lymphocytes, a process that 
might be essential for the function of lymphocyte. This hypothesis is based on 
the fact that the absence of glutamate led to impaired Th1 (Interleukin-2 (IL-2) 
and interferon-γ) and proinflammatory (IL-6 and tumor necrosis factor-alpha) 
cytokine production. However, these changes were not correlated with a decrease 
in T-cell proliferation.
3. mGluR4 and Autoimmunity in CNS
A role of mGluR4 in immune modulation was first described in an autoim-
mune disease model [17]. Fallarino et al. [17] reported that mGlu4 knockout mice 
(Grm4−/−) were highly susceptible to experimental autoimmune encephalomyelitis 
(EAE), a model of multiple sclerosis. More specifically, Grm4−/− mice and their wild-
type (WT) counterparts were immunized with myelin oligodendrocyte glycoprotein 
(MOG35–55), which can induce EAE in C57BL/6 mice. The EAE clinical scores were 
recorded periodically and a lack of mGluR4 was found to be associated with earlier 
onset, more severe, and ultimately fatal EAE in >40% of the hosts. Along with 
these changes, white matter demyelination and inflammatory infiltrates were more 
prevalent in the spinal cord of MOG-vaccinated Grm4−/− mice in comparison to their 
WT counterparts, according to the morphological changes. The phenotype has also 
been characterized in littermates as well (heterozygote breeding—with cohorts of 
mice being matched for gender and age) and the disease indications were also more 
severe in Grm4−/− and Grm4+/− mice than in WT mice. In contrast, treatment of 
N-Phenyl-7-(hydroxyimino) cyclopropa [b] chromen-1a-carboxamide (PHCCC), 
an Grm4-positive allosteric modulator led to increased resistance to EAE. This was in 
agreement with previous reports demonstrating that long-term treatment of L-AP4 
can increase the recovery rate from EAE in Lewis rats [17, 18].
There was significant infiltration of CD4+ T cells, CD8+ T cells and B220+ B cells 
in both peripheral lymphoid organs and the CNS in both Grm4−/− and WT mice, 
but the percentages of CD4+ and CD8+ T cells as well as CD11b+ and CD11c+ cells 
were significantly higher in the CNS of Grm4−/− mice at the peak of disease [17]. 
Extended studies using littermates from heterozygote breeding further showed 
that the disease course was more severe in Grm4−/− and Grm4+/− mice than in WT 
mice. The cytokine profiling of sorted CD4+ T cells from brain-infiltrating leuko-
cytes (BILs) and pooled lymph nodes demonstrated a significant increase in Rorc 
transcripts (encoding the TH17 specification factor), a reduction in Foxp3 (Treg) 
transcripts, and no change in Tbx21 (coding for Tbet; a TH1 maker) in Grm4
−/− mice 
during the neurologic signs. No changes were observed in Gata3 (a TH2 marker) in 
both groups. These data suggested that Grm4−/− tipped the balance of transcrip-
tional activation in favor of inflammatory genes in response to MOG vaccination. 
In particular, Grm4−/− favored the emergence of TH17 over Treg cells, which would 
sustain inflammation and exacerbate EAE [18].
Expression of mGluR4 was confirmed in several immune subpopulations, such 
as CD4+ T cells, CD8+ T cells, γδ T cells, B220+ B cells, CD11b+ and CD11c+ cells, 
particularly in CD4+ T and CD11c+ cells, suggesting those cells as potential targets 
for Grm4 mediated effects. The expression of mGluR4 was also confirmed in DC 
subsets in splenocytes, including conventional DCs (cDCs; CD11b+CD11chigh) and 
plasmacytoid DCs (pDCs; mPDCA1+ CD11clow). They have further shown that 
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treatment with toll-like receptor ligands such as lipopolysaccharide (LPS) and 
CpG-oligonucleotide (CpG-ODN) led to increased Grm4 expression. Modulation 
of mGluR4 expression in activated nTreg cells (CD4+ CD25+) and LPS-stimulated 
cDCs was also confirmed, further supporting that mGluR4 activation within an 
immunologic synapse contributes to the crosstalk and reciprocal influence between 
T and accessory cells [17].
IL-17-producing T helper (Th17) cells are considered mediators of autoim-
munity in multiple sclerosis and EAE. The accumulation of Th17 cells in the CNS as 
well as in the periphery is also associated with the development of demyelinating 
plaques of multiple sclerosis [19]. Fallarino et al. [17] also pointed out that the 
absence of mGlu4 in dendritic cells is key to inducing a differentiation of T helper 
cells toward the Th17 phenotype. More specifically, possible regulatory function of 
mGluR4 in the interaction between CD4+ T cells and DCs has been examined. Both 
cDCs and pDCs from Grm4−/− mice produced higher amounts of IL-6 and IL-23, 
but less IL-12 and IL-27, compared to their WT counterparts in response to LPS or 
CpG-ODN, respectively [17].
The notable results of coculturing of WT CD4+ T cell and Grm4−/− DCs demon-
strated an increase of IL-17A+ CD4+ T cells, along with a significantly reduction of 
IFN-γ producing CD4+ T cells (a portion of which also expressed IL-17A). However, 
they failed to see this effect when the coculture consisted of WT DCs and Grm4−/− T 
cells, suggesting that the effect of mGluR4 depletion was largely dependent on DCs 
in this in vitro system. The cytokine production in culture supernatants has been 
examined and there are decreased amounts of TH1-associated IL-2 in coculture sys-
tem involving Grm4−/− cDCs. IL-27 is known to counter the effect of IL-6 in direct-
ing TH17 cell development, which can limit the EAE progression. The decrease in 
IL-27 during activation of naïve CD4+ T cells might be another reason for favoring 
the emergence of Th17 cells [17].
They also suggest that activation of mGlu4 (as a result of elevated levels of gluta-
mate during the neuroinflammation) might exert a protective effect by prevent-
ing the unbalance in T helper cells. Such mechanism presents a clear therapeutic 
potential for treating autoimmune related disorders.
The underlying mechanism for Grm4-mediated immune regulation is not clear 
at present. However, there appears to be a cross-talk and reciprocal influences 
between Grm4 and indoleamine 2,3-dioxygenase 1 (IDO-1) pathways [20]. IDO1 
has been well known to be involved in generating an immunosuppressive environ-
ment through catalyzing the metabolism of tryptophan, resulting in tryptophan 
depletion and accumulation of kynurenine [21]. A protective role of IDO-1 has 
been shown in mice with different forms of EAE including acute, relapsing–remit-
ting, and adoptively transferred disease [22]. Interestingly, in addition to the direct 
immunosuppressive effect of kynurenine through inhibition of CD8+ T cells and 
activation of Treg cells, kynurenine metabolites such as cinnabarinic acid (CA) act 
as selective, although weak, orthosteric agonists of mGluR4 [23]. The therapeutic 
effect of CA in acute EAE was attenuated in Grm4−/− mice [24]. On the other 
hand, activation of Grm4 could positively impact the IDO1 pathway. Treatment 
of DCs with ADX88178, a positive allosteric modulator (PAM) of Grm4, led to 
both increased expression levels of IDO-1 and phosphorylation of IDO-1 [20]. 
These effects require a Gi-independent, alternative signaling pathway that involves 
phosphatidylinositol-3-kinase (PI3K), Src kinase, and the signaling activity of 
IDO1. Moreover, the effect of ADX88178 on the expression of several cytokines was 
impaired in IDO1−/− DCs [20]. Therefore, Grm4 and IDO1 constitute a loop that 
provides a positive feedback mechanism to amplify the immune-protective effect in 
EAE and possibly other immune-related diseases [20].
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4. mGluR4 and cancers
Most studies on the role of glutamate receptor in cancers have been focused 
on iGluRs [25, 26]. Tumor cells originated from neuronal tissues express iGluRs 
subunits and iGluRs antagonists have shown inhibitory effect on the proliferation 
of the tumor cells. Similarly, iGluRs subunits have been shown to be expressed in 
several peripheral cancers and blockade of the N-methyl-D-aspartate (NMDA) and 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) inotropic gluta-
mate receptor subtypes leads to decreased cell proliferation and migration [26].
mGluRs are also expressed in several cell lines derived from human tumors, 
including neuroblastoma, thyroid carcinoma, rhabdomyosarcoma/medulloblas-
toma, lung carcinoma, multiple myeloma, glioma, colon adenocarcinoma, astrocy-
toma, T cell leukemia, and breast carcinoma [27]. In particular, mGluR1 has been 
shown to be expressed in subsets of human melanomas [28]. Ectopic expression 
of mGluR1 in melanocytes drives the development of melanoma in mouse models. 
Pharmacological inhibition of mGluR1 led to inhibition of tumor cell growth both 
in vitro and in vivo [28]. Riluzole, an antagonist of mGluR1 signaling has advanced 
to phase II clinical trial in patients with advanced melanoma [29, 30].
The studies on the roles of mGluR4 in cancers are very limited and controversial. 
Change et al. studied the expression pattern of mGluR4 in several healthy and 
diseases-derived human tissues [31]. mGluR4 receptor expression was identified in 
68% of colorectal carcinomas, 50% of laryngeal carcinoma, and 46% breast carci-
nomas. In the case of colorectal carcinoma, overexpression of mGluR4 was corre-
lated with poor prognosis, and cell lines derived from human colorectal carcinomas 
showed increased cell invasiveness when treated with L-AP4. In another study, 
comparative proteomics was used to characterize a human colon cancer cell line that 
was resistant to 5-fluororacil (5-FU, a common chemotherapy agent). Interestingly, 
5-FU resistant cells were found to overexpress mGluR4 in comparison with parental 
cancer cells. It has been demonstrated that cell survival was increased by the group 
III mGlu receptor agonist L-AP4 in the nonresistant parent cancer cells; conversely, 
survival was synergically decreased by 5-FU and the group III receptor antagonist 
MAP4 in 5-FU-resistant cells. It is noteworthy to mention that 5-FU downregulated 
mGluR4 expression, and MAP4 has a dose dependent cytotoxic effect in both cell 
lines [32].
In contrast to the above reports, mGluR4 agonists are shown to inhibit the 
proliferation of human breast and bladder cancer cells in a GRM4-depenedt manner 
[33]. In the study by Lasek et al., the expression of mGlu4 was shown to be inversely 
correlated with the severity of human medulloblastoma [34]. After scoring the 
extent of immunoreactivity for mGlu4 in human biopsies of medulloblastoma, the 
absence of spinal metastases, cerebrospinal fluid spread, and tumor recurrence as 
well as the survival of patients were all shown to be associated with high levels of 
mGlu4 immunoreactivity. Treatment with PHCCC (which is considered a group 
I mGlu receptor antagonist but can also act as a positive allosteric modulator of 
mGlu4 receptor) reduced the proliferation of cultured medulloblastoma cells and 
inhibited the growth of medulloblastoma implants in mice. In addition, subcutane-
ous or intracranial injections of PHCCC during the first week of life reduced the 
incidence of medulloblastoma from 85 to 28% in a mutant mouse model known to 
develop the disease upon X-ray irradiation. This indicates that activation of mGlu4 
receptors also affects early events in tumorigenesis [35].
The above studies focus on the role of tumor cell-derived Grm4. It has been 
reported that the plasma levels of Glu are generally elevated in patients with carci-
noma and seem to correlate with an impairment in immune function [36]. However, 
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the role of immune cell-derived mGluR including mGluR4 has hardly been studied. 
Kansara et al. reported that Grm4−/− mice showed accelerated radiation-induced 
tumor development in an irradiation-induced osteosarcoma model [37]. Outside 
the CNS, mGluR4 is highly expressed by DCs, as well as CD4+ T cells [17]. In the 
mouse osteosarcomas, they found that mGluR4 is predominantly expressed by 
CD45+CD11c+MHC+ myeloid cells within the tumor microenvironment (TME) 
instead of tumor cells. Few CD4+ T cells were detectable to characterize mGluR4 
expression. In consistent with the study by Fallarino et al. [17] in an EAE model, 
Grm4−/− DCs isolated from the tumors showed increased expression of IL-23. 
Interestingly, high expression of IL-23 has been observed in primary osteosarcomas 
and allografted cell lines relative to normal bone, while ex-vivo cultured osteo-
sarcoma cell lines and primary tumor cells did not express IL23. A role of IL-23 in 
tumorigenesis has been well established from previous studies [38]. Indeed, IL23−/− 
mice were resistant to the irradiation-induced osteosarcoma. They hypothesized 
that knockout of Grm4 in DCs facilitates the oncogenesis of osteosarcoma through 
increased production of IL-23 [37].
We have recently shown in three murine syngeneic tumor models (B16, MC38, 
and 3LL) that either genetic knockout (Grm4−/−) or pharmacological inhibi-
tion led to significant delay in tumor growth (Wan et al., unpublished data). 
Mechanistically, perturbation of GRM4 resulted in a strong anti-tumor immunity 
by promoting nature killer (NK), CD4+ and CD8+ T cells toward an activated, 
proliferative, and functional phenotype. We have further shown that the antitumor 
activity of Grm4 antagonists can be further improved through combination with 
anti-PD-1 antibody. The differing role of Grm4 in different tumor models may 
reflect the complex functions of Grm4 in different tumor environment. More 
studies are needed to further define the roles of immune cells-derived Grm4 and its 
potential as a novel therapeutic target for cancer immunotherapy.
5. Conclusions
Although the neurological function of GRM4 in CNS has been well established, 
its role in modulating immune response just began to be appreciated. GRM4 is 
expressed in various immune cells and loss of GRM4 function in immune cells led to 
sensitization to EAE. GRM4 selective agonists may hold potential as a novel therapy 
for autoimmune disorders of CNS. GRM4 is also expressed in various cancer cells, 
however, conflicting results have been reported regarding whether GRM4 promotes 
or inhibits tumor cell proliferation. The role of immune cells-derived GRM4 in 
antitumor immunity is also controversial and may reflect the complex function of 
GRM4 in different tumor microenvironment. Further studies using more defined 
animal models and selective GRM4 modulators may not only advance our under-
standing of the complex immunobiology of GRM4 but also lead to the development 
of a new immunotherapy for the treatment of cancer.
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